Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Trabectedin 4Doxorubicin 4toripalimab 2brigimadlin 2belinostat 2Fulvestrant 2Dexamethasone 2tanespimycin 1soblidotin 1siremadlin 1selinexor 1ridaforolimus 1ribociclib 1pembrolizumab 1olaratumab 1milademetan 1enzalutamide 1cemiplimab 1atezolizumab 1TTI-621 1Sugars 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Letrozole 1Injections 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liposarcoma × Docetaxel × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡